Adverse Event Management
Study Examines Patient Preference in Patient-Reported Outcome Tracking
April 06, 2021
Article
Patient-reported outcomes (PRO) hold valuable information on how patients are handling cancer treatment. Recent research analyzed which methods of PROs patients prefer.
T-DM1 Toxicity Management in Breast Cancer
April 05, 2021
Article
Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.
Adverse Event Management: What’s the Limiting Factor?
March 24, 2021
Article
We want to hear from you: what is the limiting factor in managing adverse events in patients with cancer?
Preventing Paclitaxel-Related Infusion Reactions
March 24, 2021
Article
Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.
Depression History and Breast Cancer Treatments May Affect Fatigue Levels
March 03, 2021
Article
Baseline fatigue levels, prior psychosocial history, and cancer treatment may all affect the fatigue trajectory in women with breast cancer.
Better Treatment Needed for Androgen Receptor Adverse Events
February 23, 2021
Article
While the majority of patients on androgen receptor therapy experienced adverse events, more than a third did not have them resolved.
Patient Perceptions, Other Factors Linked to Fear of Recurrence
February 19, 2021
Article
Fear of cancer recurrence is a common plight for people after they have completed cancer treatment, and recent research analyzed which patient characteristics were associated with higher rates of fear of recurrence.
High TMB, Adverse Events May Predict Immunotherapy Response in mUC
February 17, 2021
Article
Patients with metastatic urothelial carcinoma with higher tumor mutational burden and who experienced immune-related adverse events tended to have higher response rates to immune checkpoint inhibitor.
Sapanisertib: Poor Activity, More AEs in mRCC
February 13, 2021
Article
Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma (mRCC) regardless of mTOR or PTEN status.
COVID-19 Amplifies Stress, Loneliness in Cancer Survivors
February 12, 2021
Article
The COVID-19 pandemic increased rates of stress in the general public, adding to that of survivors who may already be feeling anxious.